Hippocratic AI expanded into life sciences through the acquisition of Grove AI, adding clinical trial–focused agentic AI to its existing patient-facing healthcare platform. The move establishes a dedicated life sciences division led by Ahad Wahid, alongside an executive advisory panel drawn from major biopharma, medtech, and research institutions. The expansion builds on Hippocratic AI’s mission to deliver safety-focused, non-diagnostic AI systems that address workforce and operational gaps across regulated healthcare environments.
Grove AI brings technology designed to automate clinical trial operations, including participant pre-screening, follow-ups, and complex workflow orchestration, with its AI reportedly supporting more than 10 million patient interactions across life sciences R&D over the past year. According to co-founder and CEO Munjal Shah, the acquisition reflects the need for deeply specialized models and rigorous safety architectures to operate in highly regulated life sciences settings. With more than $400 million raised and a valuation around $3.5 billion, Hippocratic AI is positioning life sciences as a core growth pillar alongside its provider and payer-focused healthcare agent deployments.